Hasil Pencarian - Christopher Hackenbruch

  • Menampilkan 1 - 6 hasil dari 6
Perbaiki Hasil
  1. 1
    Long-Term Follow-Up of COVID-19 Convalescents—Immune Response Associated with Reinfection Rate and Symptoms

    Long-Term Follow-Up of COVID-19 Convalescents—Immune Response Associated with Reinfection Rate and Symptoms oleh Anna Seller, Christopher Hackenbruch, Juliane S. Walz, Annika Nelde, Jonas S. Heitmann

    Diterbitkan 2023-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3)

    Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal can... oleh Susanne Jung, Susanne Jung, Susanne Jung, Richard F. Schlenk, Richard F. Schlenk, Christopher Hackenbruch, Christopher Hackenbruch, Christopher Hackenbruch, Sandra S.L. Roldan Pinzon, Michael Bitzer, Martin Pflügler, Juliane S. Walz, Juliane S. Walz, Juliane S. Walz, Gundram Jung, Jonas S. Heitmann, Jonas S. Heitmann, Jonas S. Heitmann, Helmut R. Salih, Helmut R. Salih

    Diterbitkan 2024-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Elevated SARS-CoV-2-Specific Antibody Levels in Patients with Post-COVID Syndrome

    Elevated SARS-CoV-2-Specific Antibody Levels in Patients with Post-COVID Syndrome oleh Christopher Hackenbruch, Yacine Maringer, Christian M. Tegeler, Juliane S. Walz, Annika Nelde, Jonas S. Heitmann

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens

    iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens oleh Alexander Englisch, Alexander Englisch, Alexander Englisch, Clara Hayn, Clara Hayn, Susanne Jung, Susanne Jung, Susanne Jung, Jonas S. Heitmann, Jonas S. Heitmann, Jonas S. Heitmann, Christopher Hackenbruch, Christopher Hackenbruch, Christopher Hackenbruch, Yacine Maringer, Yacine Maringer, Annika Nelde, Annika Nelde, Marcel Wacker, Marcel Wacker, Monika Denk, Lisa Zieschang, Christine Kammer, Peter Martus, Helmut R. Salih, Helmut R. Salih, Juliane S. Walz, Juliane S. Walz, Juliane S. Walz

    Diterbitkan 2024-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients

    AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell an... oleh Susanne Jung, Susanne Jung, Susanne Jung, Annika Nelde, Annika Nelde, Yacine Maringer, Yacine Maringer, Monika Denk, Monika Denk, Monika Denk, Lisa Zieschang, Lisa Zieschang, Lisa Zieschang, Christine Kammer, Christine Kammer, Melek Özbek, Melek Özbek, Melek Özbek, Peter Martus, Christopher Hackenbruch, Christopher Hackenbruch, Christopher Hackenbruch, Alexander Englisch, Alexander Englisch, Alexander Englisch, Jonas S. Heitmann, Jonas S. Heitmann, Jonas S. Heitmann, Helmut R. Salih, Helmut R. Salih, Juliane S. Walz, Juliane S. Walz, Juliane S. Walz, Juliane S. Walz

    Diterbitkan 2024-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion

    FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellu... oleh Christopher Hackenbruch, Christopher Hackenbruch, Christopher Hackenbruch, Jens Bauer, Jens Bauer, Jonas S. Heitmann, Jonas S. Heitmann, Jonas S. Heitmann, Yacine Maringer, Yacine Maringer, Annika Nelde, Annika Nelde, Monika Denk, Monika Denk, Lisa Zieschang, Lisa Zieschang, Christine Kammer, Christine Kammer, Birgit Federmann, Birgit Federmann, Birgit Federmann, Susanne Jung, Susanne Jung, Susanne Jung, Peter Martus, Nisar P. Malek, Nisar P. Malek, Nisar P. Malek, Nisar P. Malek, Nisar P. Malek, Konstantin Nikolaou, Konstantin Nikolaou, Konstantin Nikolaou, Helmut R. Salih, Helmut R. Salih, Michael Bitzer, Michael Bitzer, Michael Bitzer, Michael Bitzer, Juliane S. Walz, Juliane S. Walz, Juliane S. Walz, Juliane S. Walz

    Diterbitkan 2024-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: